ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
Retrieved on:
Wednesday, February 12, 2020
BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL.The current annual market for this product is approximately $29 million, according to IQVIA.This launch represents ANI's third generic product introduction in 2020.
Key Points:
- BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ --ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL.The current annual market for this product is approximately $29 million, according to IQVIA.This launch represents ANI's third generic product introduction in 2020.
- Arthur S. Przybyl, ANI's President and CEO commented, "This is the twelfth product that ANI has successfully launched from our library of discontinued NDAs and ANDAs.
- Sulfamethoxazole and Trimethoprim Oral Suspension is indicated in the treatment and prevention of various infections proven or strongly suspected to be caused by susceptible bacteria which include urinary tract infections, acute otitis media, bronchitis, shigellosis, Pneumocystis jirovecipneumonia, and traveler's diarrhea.
- ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.